ACADIA PHARMACEUTICALS INC (ACAD) Stock Fundamental Analysis
USA - NASDAQ:ACAD - US0042251084 - Common Stock
21.54 USD
-0.05 (-0.23%)
21.56 USD
+0.02 (+0.09%)
Taking everything into account, ACAD scores 6 out of 10 in our fundamental rating. ACAD was compared to 536 industry peers in the Biotechnology industry. While ACAD has a great health rating, its profitability is only average at the moment. ACAD is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, ACAD could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
In the past year ACAD was profitable.
In the past year ACAD had a positive cash flow from operations.
ACAD had negative earnings in 4 of the past 5 years.
In multiple years ACAD reported negative operating cash flow during the last 5 years.
1.2 Ratios
ACAD has a Return On Assets of 18.13%. This is amongst the best in the industry. ACAD outperforms 96.64% of its industry peers.
With an excellent Return On Equity value of 27.01%, ACAD belongs to the best of the industry, outperforming 97.01% of the companies in the same industry.
The Return On Invested Capital of ACAD (8.85%) is better than 93.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.13% | ||
| ROE | 27.01% | ||
| ROIC | 8.85% |
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 21.80%, ACAD belongs to the top of the industry, outperforming 94.96% of the companies in the same industry.
With an excellent Operating Margin value of 8.86%, ACAD belongs to the best of the industry, outperforming 91.79% of the companies in the same industry.
Looking at the Gross Margin, with a value of 91.97%, ACAD belongs to the top of the industry, outperforming 92.35% of the companies in the same industry.
In the last couple of years the Gross Margin of ACAD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.86% | ||
| PM (TTM) | 21.8% | ||
| GM | 91.97% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
2. Health
2.1 Basic Checks
ACAD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, ACAD has more shares outstanding
Compared to 5 years ago, ACAD has more shares outstanding
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 4.65 indicates that ACAD is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.65, ACAD is in the better half of the industry, outperforming 74.81% of the companies in the same industry.
There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.65 |
ROIC/WACC0.92
WACC9.58%
2.3 Liquidity
A Current Ratio of 2.91 indicates that ACAD has no problem at all paying its short term obligations.
ACAD has a worse Current ratio (2.91) than 64.55% of its industry peers.
ACAD has a Quick Ratio of 2.83. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
ACAD has a worse Quick ratio (2.83) than 64.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.91 | ||
| Quick Ratio | 2.83 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 150.00% over the past year.
Looking at the last year, ACAD shows a quite strong growth in Revenue. The Revenue has grown by 14.41% in the last year.
The Revenue has been growing by 23.08% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)150%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)14.41%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%9.34%
3.2 Future
The Earnings Per Share is expected to grow by 41.41% on average over the next years. This is a very strong growth
Based on estimates for the next years, ACAD will show a quite strong growth in Revenue. The Revenue will grow by 10.77% on average per year.
EPS Next Y19.39%
EPS Next 2Y34.23%
EPS Next 3Y42.2%
EPS Next 5Y41.41%
Revenue Next Year9.96%
Revenue Next 2Y10.88%
Revenue Next 3Y10.8%
Revenue Next 5Y10.77%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
ACAD is valuated quite expensively with a Price/Earnings ratio of 47.87.
Based on the Price/Earnings ratio, ACAD is valued cheaply inside the industry as 91.79% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of ACAD to the average of the S&P500 Index (27.76), we can say ACAD is valued expensively.
A Price/Forward Earnings ratio of 24.90 indicates a rather expensive valuation of ACAD.
Based on the Price/Forward Earnings ratio, ACAD is valued cheaper than 91.60% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.21. ACAD is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.87 | ||
| Fwd PE | 24.9 |
4.2 Price Multiples
ACAD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ACAD is cheaper than 93.47% of the companies in the same industry.
ACAD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ACAD is cheaper than 93.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 41.14 | ||
| EV/EBITDA | 22.82 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of ACAD may justify a higher PE ratio.
A more expensive valuation may be justified as ACAD's earnings are expected to grow with 42.20% in the coming years.
PEG (NY)2.47
PEG (5Y)N/A
EPS Next 2Y34.23%
EPS Next 3Y42.2%
5. Dividend
5.1 Amount
No dividends for ACAD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
21.54
-0.05 (-0.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners102.78%
Inst Owner Change0%
Ins Owners0.3%
Ins Owner Change1.17%
Market Cap3.63B
Analysts76.15
Price Target29.64 (37.6%)
Short Float %4.76%
Short Ratio3.9
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.63%
Min EPS beat(2)-3.19%
Max EPS beat(2)14.46%
EPS beat(4)2
Avg EPS beat(4)-13.96%
Min EPS beat(4)-109.07%
Max EPS beat(4)41.97%
EPS beat(8)5
Avg EPS beat(8)7.72%
EPS beat(12)7
Avg EPS beat(12)13.12%
EPS beat(16)10
Avg EPS beat(16)17.21%
Revenue beat(2)1
Avg Revenue beat(2)-0.42%
Min Revenue beat(2)-0.93%
Max Revenue beat(2)0.08%
Revenue beat(4)1
Avg Revenue beat(4)-2.63%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.08%
Revenue beat(8)4
Avg Revenue beat(8)-0.28%
Revenue beat(12)5
Avg Revenue beat(12)-0.9%
Revenue beat(16)7
Avg Revenue beat(16)-1.31%
PT rev (1m)-2.24%
PT rev (3m)7.61%
EPS NQ rev (1m)0.33%
EPS NQ rev (3m)9.99%
EPS NY rev (1m)-0.49%
EPS NY rev (3m)1.73%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.83%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.87 | ||
| Fwd PE | 24.9 | ||
| P/S | 3.57 | ||
| P/FCF | 41.14 | ||
| P/OCF | 19.33 | ||
| P/B | 4.42 | ||
| P/tB | 5.13 | ||
| EV/EBITDA | 22.82 |
EPS(TTM)0.45
EY2.09%
EPS(NY)0.86
Fwd EY4.02%
FCF(TTM)0.52
FCFY2.43%
OCF(TTM)1.11
OCFY5.17%
SpS6.04
BVpS4.87
TBVpS4.2
PEG (NY)2.47
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.13% | ||
| ROE | 27.01% | ||
| ROCE | 10.08% | ||
| ROIC | 8.85% | ||
| ROICexc | 59.33% | ||
| ROICexgc | 412.73% | ||
| OM | 8.86% | ||
| PM (TTM) | 21.8% | ||
| GM | 91.97% | ||
| FCFM | 8.67% |
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
F-Score6
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 729.13% | ||
| Cap/Sales | 9.78% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 180.83% | ||
| Profit Quality | 39.76% | ||
| Current Ratio | 2.91 | ||
| Quick Ratio | 2.83 | ||
| Altman-Z | 4.65 |
F-Score6
WACC9.58%
ROIC/WACC0.92
Cap/Depr(3y)241.55%
Cap/Depr(5y)203.25%
Cap/Sales(3y)1.86%
Cap/Sales(5y)1.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)150%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
EPS Next Y19.39%
EPS Next 2Y34.23%
EPS Next 3Y42.2%
EPS Next 5Y41.41%
Revenue 1Y (TTM)14.41%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%9.34%
Revenue Next Year9.96%
Revenue Next 2Y10.88%
Revenue Next 3Y10.8%
Revenue Next 5Y10.77%
EBIT growth 1Y307.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.53%
EBIT Next 3Y32.73%
EBIT Next 5Y43.57%
FCF growth 1Y218.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y647.78%
OCF growth 3YN/A
OCF growth 5YN/A